Post-HTS case report and structural alert

Promiscuous 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR

Jayme L. Dahlin, J. Willem M Nissink, Subhashree Francis, Jessica M. Strasser, Kristen John, Zhiguo Zhang, Michael A. Walters

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Despite its wide use, not every high-throughput screen (HTS) yields chemical matter suitable for drug development campaigns, and seldom are 'go/no-go' decisions in drug discovery described in detail. This case report describes the follow-up of a 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one active from a cell-free HTS to identify small-molecule inhibitors of Rtt109-catalyzed histone acetylation. While this compound and structural analogs inhibited Rtt109-catalyzed histone acetylation in vitro, further work on this series was halted after several risk mitigation strategies were performed. Compounds with this chemotype had a poor structure-activity relationship, exhibited poor selectivity among other histone acetyltransferases, and tested positive in a β-lactamase counter-screen for chemical aggregates. Furthermore, ALARM NMR demonstrated compounds with this chemotype grossly perturbed the conformation of the La protein. In retrospect, this chemotype was flagged as a 'frequent hitter' in an analysis of a large corporate screening deck, yet similar compounds have been published as screening actives or chemical probes versus unrelated biological targets. This report - including the decision-making process behind the 'no-go' decision - should be informative for groups engaged in post-HTS triage and highlight the importance of considering physicochemical properties in early drug discovery.

Original languageEnglish (US)
Pages (from-to)4740-4752
Number of pages13
JournalBioorganic and Medicinal Chemistry Letters
Volume25
Issue number21
DOIs
StatePublished - Jun 2 2015

Fingerprint

Drug Discovery
Acetylation
Histones
Throughput
Nuclear magnetic resonance
Histone Acetyltransferases
Protein Conformation
Triage
Screening
Structure-Activity Relationship
Decision Making
Conformations
Decision making
Pharmaceutical Preparations
Molecules
3-hydroxy-2H-pyrrol-2-one
Proteins
In Vitro Techniques

Keywords

  • Chemical aggregation
  • Drug discovery
  • High-throughput screening
  • PAINS
  • Pan-assay interference compounds
  • Structureactivity relationships

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Molecular Biology
  • Molecular Medicine
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Post-HTS case report and structural alert : Promiscuous 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR. / Dahlin, Jayme L.; Nissink, J. Willem M; Francis, Subhashree; Strasser, Jessica M.; John, Kristen; Zhang, Zhiguo; Walters, Michael A.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 25, No. 21, 02.06.2015, p. 4740-4752.

Research output: Contribution to journalArticle

Dahlin, Jayme L. ; Nissink, J. Willem M ; Francis, Subhashree ; Strasser, Jessica M. ; John, Kristen ; Zhang, Zhiguo ; Walters, Michael A. / Post-HTS case report and structural alert : Promiscuous 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR. In: Bioorganic and Medicinal Chemistry Letters. 2015 ; Vol. 25, No. 21. pp. 4740-4752.
@article{e9cc14ac0e144d5cb6ac74d88a270d73,
title = "Post-HTS case report and structural alert: Promiscuous 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR",
abstract = "Despite its wide use, not every high-throughput screen (HTS) yields chemical matter suitable for drug development campaigns, and seldom are 'go/no-go' decisions in drug discovery described in detail. This case report describes the follow-up of a 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one active from a cell-free HTS to identify small-molecule inhibitors of Rtt109-catalyzed histone acetylation. While this compound and structural analogs inhibited Rtt109-catalyzed histone acetylation in vitro, further work on this series was halted after several risk mitigation strategies were performed. Compounds with this chemotype had a poor structure-activity relationship, exhibited poor selectivity among other histone acetyltransferases, and tested positive in a β-lactamase counter-screen for chemical aggregates. Furthermore, ALARM NMR demonstrated compounds with this chemotype grossly perturbed the conformation of the La protein. In retrospect, this chemotype was flagged as a 'frequent hitter' in an analysis of a large corporate screening deck, yet similar compounds have been published as screening actives or chemical probes versus unrelated biological targets. This report - including the decision-making process behind the 'no-go' decision - should be informative for groups engaged in post-HTS triage and highlight the importance of considering physicochemical properties in early drug discovery.",
keywords = "Chemical aggregation, Drug discovery, High-throughput screening, PAINS, Pan-assay interference compounds, Structureactivity relationships",
author = "Dahlin, {Jayme L.} and Nissink, {J. Willem M} and Subhashree Francis and Strasser, {Jessica M.} and Kristen John and Zhiguo Zhang and Walters, {Michael A.}",
year = "2015",
month = "6",
day = "2",
doi = "10.1016/j.bmcl.2015.08.020",
language = "English (US)",
volume = "25",
pages = "4740--4752",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "21",

}

TY - JOUR

T1 - Post-HTS case report and structural alert

T2 - Promiscuous 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR

AU - Dahlin, Jayme L.

AU - Nissink, J. Willem M

AU - Francis, Subhashree

AU - Strasser, Jessica M.

AU - John, Kristen

AU - Zhang, Zhiguo

AU - Walters, Michael A.

PY - 2015/6/2

Y1 - 2015/6/2

N2 - Despite its wide use, not every high-throughput screen (HTS) yields chemical matter suitable for drug development campaigns, and seldom are 'go/no-go' decisions in drug discovery described in detail. This case report describes the follow-up of a 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one active from a cell-free HTS to identify small-molecule inhibitors of Rtt109-catalyzed histone acetylation. While this compound and structural analogs inhibited Rtt109-catalyzed histone acetylation in vitro, further work on this series was halted after several risk mitigation strategies were performed. Compounds with this chemotype had a poor structure-activity relationship, exhibited poor selectivity among other histone acetyltransferases, and tested positive in a β-lactamase counter-screen for chemical aggregates. Furthermore, ALARM NMR demonstrated compounds with this chemotype grossly perturbed the conformation of the La protein. In retrospect, this chemotype was flagged as a 'frequent hitter' in an analysis of a large corporate screening deck, yet similar compounds have been published as screening actives or chemical probes versus unrelated biological targets. This report - including the decision-making process behind the 'no-go' decision - should be informative for groups engaged in post-HTS triage and highlight the importance of considering physicochemical properties in early drug discovery.

AB - Despite its wide use, not every high-throughput screen (HTS) yields chemical matter suitable for drug development campaigns, and seldom are 'go/no-go' decisions in drug discovery described in detail. This case report describes the follow-up of a 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one active from a cell-free HTS to identify small-molecule inhibitors of Rtt109-catalyzed histone acetylation. While this compound and structural analogs inhibited Rtt109-catalyzed histone acetylation in vitro, further work on this series was halted after several risk mitigation strategies were performed. Compounds with this chemotype had a poor structure-activity relationship, exhibited poor selectivity among other histone acetyltransferases, and tested positive in a β-lactamase counter-screen for chemical aggregates. Furthermore, ALARM NMR demonstrated compounds with this chemotype grossly perturbed the conformation of the La protein. In retrospect, this chemotype was flagged as a 'frequent hitter' in an analysis of a large corporate screening deck, yet similar compounds have been published as screening actives or chemical probes versus unrelated biological targets. This report - including the decision-making process behind the 'no-go' decision - should be informative for groups engaged in post-HTS triage and highlight the importance of considering physicochemical properties in early drug discovery.

KW - Chemical aggregation

KW - Drug discovery

KW - High-throughput screening

KW - PAINS

KW - Pan-assay interference compounds

KW - Structureactivity relationships

UR - http://www.scopus.com/inward/record.url?scp=84944151490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944151490&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2015.08.020

DO - 10.1016/j.bmcl.2015.08.020

M3 - Article

VL - 25

SP - 4740

EP - 4752

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 21

ER -